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Abstract: Doxorubicin is a cytotoxic anthracycline derivative that has been used as a chemotherapeu-
tic in many different forms of human cancer with some success. However, doxorubicin treatment
has several side-effects, the most serious of which is cardiomyopathy, that can be fatal. Doxorubicin
encapsulation in PEGylated liposomes (Doxil®) has been shown to increase tumour localisation and
decrease cardiotoxicity. Conversely, the stability of such liposomes also leads to increased circula-
tion times and accumulation in the skin, resulting in palmar planter erythrodysesthesia, while also
limiting release of the drug at the tumour site. Specific targeting of such liposomes to tumour cells
has been attempted using various receptor-specific peptides and antibodies. However, targeting a
single epitope limits the likely number of tumour targets and increases the risk of tumour resistance
through mutation. In this report, Doxil® was coupled to peptide sequence p700 derived from tissue
inhibitor of metalloproteinase 3. This Doxil® -P700 complex results in an approximately 100-fold
increase in drug uptake, relative to Doxil® alone, by both mouse and human breast cancer cells and
immortalised vascular cells resulting in an increase in cytotoxicity. Using p700 to target liposomes in
this way may enable specific delivery of doxorubicin or other drugs to a broad range of cancers.
Keywords: angiogenesis; doxorubicin; TIMP3; VEGFR2
1. Introduction
Doxorubicin is a well-established cytotoxic anthracycline derivative that has been
used to successfully treat many different forms of human cancer, including breast cancer,
soft tissue sarcomas, multiple myeloma and some leukaemia’s. Doxorubicin’s mechanism
of action primarily involves intercalation of both chromosomal and mitochondrial DNA
and inhibition of topoisomerase II, an enzyme that relaxes the DNA making it accessible to
DNA polymerase, thus inhibiting DNA replication. However, doxorubicin binds to many
cellular proteins in addition to topoisomerase, and also results in free radical production,
increasing DNA damage and activation of apoptosis (reviewed in [1]). However, the
application of the drug is limited due to a wide range of serious side-effects, such as
liver and kidney damage and cardiotoxicity [2], and these restrict dosing regimens and,
therefore, potential efficacy.
Novel drug delivery systems have since been employed in an attempt to limit such
toxicity and improve targeting of these drugs. For instance, there is good evidence that
encapsulation of cytotoxic drugs in liposomes helps alleviate the side effects and at the
same time improves delivery [3–5]. In fact, the encapsulation of doxorubicin in PEGylated
(polyethylene glycol-coated) liposomes (e.g., Doxil®/Caelyx®) has been demonstrated to
improve its delivery and minimise side effects [6,7] by decreasing uptake by the mononu-
clear phagocyte system in the liver and spleen, greatly increasing circulation time and
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decreasing cardiotoxicity. Localisation is dependent on micelle size, preventing penetration
of normal tissue, but allowing accumulation in cancer tissue with its abnormal, leaky
vasculature. This is known as the enhanced permeability and retention (EPR) effect of
tumours [8]. However, the stability of PEGylated liposomes can result in slow release of the
liposomal content around the tumour, reducing cytotoxicity to the extent that there may be
no net benefit over non-encapsulated drugs [9]. In addition, drugs released extracellularly
into the tumour microenvironment may not be able to overwhelm the pumping action
of multidrug resistant transporters. Moreover, one of the side-effects of Doxil® is palmar
planter erythrodysesthesia (PPE or hand-foot syndrome, a skin condition that particularly
affects these limbs), probably due to increased circulation times resulting in accumulation
of liposomes in capillaries below the skin [10]. This could possibly explain why liposomal
doxorubicin only has a marginal effect on tumours that are refractory to most conventional
chemotherapeutics—the exception to this being the AIDS-related skin cancer, Kaposi’s
sarcoma, where accumulation in the skin is advantageous [11].
For this reason, modified liposomal formulations have been investigated that might
enable more specific targeting of the drug to the tumour microenvironment and enhance
uptake. These include the addition of peptides and antibodies that can serve as ligands
to specific receptors or antigens that are uniquely expressed by tumour cells [12–14], as
well as cytosolic/nuclear membrane penetrating peptides, such as those derived from the
human immunodeficiency virus type-1 (HIV-1) transactivating transcriptional factor (TAT)
protein, which contains an oligoarginine sequence that facilitates cellular entry [15].
We have previously identified a short 16 amino acid fragment of the C-terminus
of TIMP3, designated as p700. This short peptide is present in loops 4 and 5 of full
length TIMP3 that potently inhibits VEGFR2 [16]. In addition, p700 exhibits a broader
binding specificity for VEGFR1, VEGFR3, PDGFRα, FGFR1, FDFR2α, FDFR3, and FDFR4.
Interestingly, VEGFR2 and VEGFR3 are highly expressed within the tumour vasculature as
well as in malignant breast, lung and colorectal tumours [17]. VEGFR1 is highly expressed
in breast, prostatic, pancreatic and colorectal cancers [18–20], in addition to melanoma
and leukaemia [21,22]. Additionally, FGF and PDGF receptors have been shown to be
upregulated in tumours and/or tumour vasculature in colorectal, prostate, breast, ovarian,
lung, and pancreatic cancers [23–25].
While it has been shown that it is possible to directly couple doxorubicin to cancer
targeting peptides via a hydrolysable cross-linker, increasing specificity for cancer cells [26],
there are several disadvantages of this approach. Firstly, modification in this way requires
quite complex chemistry; secondly, modification of the drug may impair efficacy and,
finally, the number of molecules of doxorubicin delivered will be equal to the number
of target receptors, potentially reducing dosage to below the therapeutic threshold. This
approach also assumes that the targeting peptide is internalised by the cells, and this was
not known for p700.
An alternative strategy would be to couple p700 to the surface of a liposomal encap-
sulated doxorubicin, such as Doxil®. This has several potential advantages over direct
coupling. Firstly, the chemistry is potentially more straight-forward and does not modify
the doxorubicin itself. Secondly, one receptor can potentially enable delivery of many
molecules of doxorubicin. Thirdly, each liposome can be coated in many copies of the
peptide, potentially greatly enhancing avidity to the cell. Lastly, even if the p700 peptide is
not internalised by the cell, localisation of the liposomes to the cell surface may still enable
delivery of a therapeutic dose of Dox.
This study aimed to couple p700 to the surface of Doxil® and determine the effect of
coupling on binding, internalisation and cytotoxicity of the Doxil-p700 complex, relative
to Doxil alone, by both human and mouse breast cancer cell lines and by primary human
dermal microvascular endothelial cells and a mouse endothelial cell line.
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2. Materials and Methods
2.1. H5V, 4T1 and MCF-7 Cell Culture
H5V cells are derived from mouse cardiac endothelial cells and express both VEGFR1
and VEGFR2. In particular, the phosphorylation of VEGFR2 in response to VEGF can read-
ily be detected [27]. 4T1 cells are derived from a mouse mammary gland tumour and when
grafted into BALB/c mice, represent a well-established animal model of metastatic human
breast cancer [28,29]. MCF-7 cells are derived from human oestrogen and progesterone
receptor positive invasive ductal carcinoma cells and have low metastatic potential.
H5V and 4T1 cell lines were grown in DMEM high glucose (4.5 g/L) media (for H5V)
containing 1:1 potassium penicillin/streptomycin sulphate solution (stock 10,000 U/mL)
at 10 µL/mL, 10% FBS, 2 mM L-glutamine and 56 mM of sodium bicarbonate (NaHCO3)
at 37 ◦C and 5% CO2. MCF-7 cells on the other hand were cultured in Dulbecco’s
Modified Eagle Medium (DMEM-F12) that was supplemented with 10% FBS, 1% peni-
cillin/streptomycin, non-essential amino acids (0.1 mM), Insulin (10 µg/mL), and Sodium
pyruvate (1 mM).
Primary human dermal microvascular endothelial cells (HuDMECs) used in this
study were obtained from PromoCell, Heidelberg, Germany. HuDMEC cells were grown
in endothelial cell growth medium, supplemented with 5% FCS, 1 µg/mL hydrocortisone,
10 ng/mL EGF and 0.4% Endothelial Cell Growth Supplement/Heparin (ECGS/H) at
37 ◦C and 5% CO2.
2.2. Conjugation of p700 Peptide to PEGylated Liposomal Doxorubicin
Dibenzocyclooctyl (DBCO)-functionalised, PEGylated-liposomal doxorubicin (Doxil®)
was purchased from Encapsula® Nanomedicines (Brentwood, TN, USA). Empty DBCO-
functionalised liposomes (without doxorubicin) were also purchased from the same sup-
plier for use as a negative control. Approximately 1% of the lipid in the liposomes com-
prised 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)-PEG-DBCO with the mo-
larity of DBCO groups in the stock solutions approximately 220¦ÌM. In the liposomes
containing the active drug, (Doxil®), the doxorubicin concentration was 2 mg/mL. Stock
solutions were stored at 4 ◦C for up to one month.
Custom synthesis of an azide-functionalised, FITC-labelled p700 peptide, with a
twelve-carbon polyethylene glycol spacer (p700-FITC), and an identical control but lacking
the p700 peptide sequence (control-FITC), was carried out by Cambridge Research Bio-
chemicals (Cambridge, UK) (see Table 1). Both p700-FITC and control-FITC were dissolved
in water to make 3.3 mM stock solutions. Stocks were then stored at −20 ◦C.
Table 1. Structure of p700-FITC and control FITC.
Abbreviation Molecular Weight Structure
Control-FITC 1159.5 Azido-PEG12-Lys(5-FITC)-amide
P700-FITC 3032.4 Azido-PEG12-KIKSCYYLPCFVTSKN-
Lys(5-FITC)-amide
p700-FITC or control-FITC were coupled to DBCO-Doxil® or empty DBCO liposome
by mixing 250 µL (55 × 10−9 moles DBCO) liposome stock and 50 µL (165 × 10−9 moles)
of the azido-peptide stock and allowing the reaction to proceed with gentle agitation for at
least 4 h at room temperature and then overnight at 4 ◦C in the dark.
Purification of the coupled products was carried out by cellulose ester membrane
dialysis using the Float-a-Lyzer G2 (Spectrum®Labs, Rockleigh, NJ, USA,) with a 100 KDa
molecular weight cut off, according to the manufacturer’s instructions. Dialysis was
performed at 4 ◦C against three changes of 1 L PBS after 4, 6, and 12 h. Final volumes
following dialysis were variable and made up to 500 µL with PBS. Based on a starting
volume of Doxil of 250 µL, and assuming all the DBCO groups reacted with the azido-
peptide, the final concentration of p700 in the final coupled stock was estimated to be
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110 µM, with a final doxorubicin concentration of 1 mg/mL (1.7 mM). Purified stock
conjugate solutions were stored at 4 ◦C in the dark and used within 2 weeks.
2.3. Confirmation of Coupling by Flow Cytometry
Flow cytometry was used to confirm coupling of FITC-labelled peptide to liposomal
doxorubicin. Briefly, 30 µL of the post-dialysis sample was diluted ten-fold with PBS and
assayed using a BD LSRII flow cytometer. Samples were excited using the blue laser at
an excitation wavelength of 488 nM and emissions of 530 nM and 575 nM were used to
detect green fluorescence (FITC) and red auto-fluorescence (doxorubicin), respectively.
Uncoupled, empty liposomes were used to set the negative values for both channels, and
uncoupled Doxil® was used as a positive control for the red channel and p700-FITC as a
positive control for the green channel. Data were analysed using FlowJo software.
2.4. Confirmation of Cellular Binding of p700-Conjugated Liposomal Doxorubicin
Cellular binding of the p700-conjugated liposomal doxorubicin to the human and
mouse breast cancer cell lines MCF-7 and 4T1 (ATCC, Teddington, UK), respectively, was
evaluated by flow cytometry (refer to Supplement Data, S1). The mouse cardiac endothelial
cell line, H5V (a kind gift from Dr Annunciata Vecchi, Istituto Clinico Humanitas, Rozzano,
Italy), which expresses high levels of VEGFR2 [27] was used as a positive control, and
primary human dermal microvascular endothelial cells (HuDMEC–PromoCell, Heidelberg,
Germany), were used to determine uptake by normal endothelial cells. Cells were cultured
overnight in a 6-well plate at a density of 5 × 104 per well for H5V, MCF-7 and 4T1, and
1 × 105 per well, for HuDMECs (due to their longer doubling time). To each well containing
2 mL culture media, 5 µL of either Doxil®-p700-FITC or Doxil-FITC stock solution (i.e.,
275 nM peptide) was added and incubated at 37 ◦C for 4 h in the dark. The media was then
removed and the cells washed once with PBS.
To detach cells, 800 µL of Accutase (SIGMA, UK, Gillingham, Dorset) was then added
to each well and incubated for 2–3 min at 37 ◦C. Culture media (800 µL) was added to
stop the Accutase action and the cell suspension transferred to a polystyrene falcon tube
and spun for 5 min at 500× g. The supernatant was removed and cell pellet resuspended
in 300 µL FACS buffer (Dulbecco’s phosphate buffer saline (DPBS) containing 0.2% (w/v)
bovine serum albumin and 0.1% (w/v) sodium azide).
The samples were then examined on an LSR II flow cytometer using compensated-
blue laser at excitation wavelength of 488 nM and emissions of 530 nM with 10,000 events
collected. Using FlowJo software, data from treated and untreated cells were plotted as side
incidental light scatter (SSC) against green fluorescence. For each sample, the percentage of
cells with green fluorescence intensity above that of untreated cells was then determined.
2.5. Confirmation to Cellular Uptake of p700-Conjugated Liposomal Doxorubicin
Cellular uptake and localisation of the p700-conjugated liposomal doxorubicin (Doxil®-
p700-FITC) by MCF-7, 4T1, H5V and HuDMEC cells was evaluated by confocal microscopy.
Cells were cultured overnight on a 4-well glass chamber slide (Nunc Lab-Tek®II, Thermo
Fisher Scientific, UK, Loughborough) at a density of 3 × 104 per well (for H5V, MCF-7 and
4T1) and 5 × 104 per well (for HuDMECs). To each well containing 700 µL media, 1.75 µL
of Doxil®-p700-FITC; Doxil-FITC or empty liposome-p700-FITC (lacking doxorubicin)
stock solution was added (equivalent to 275 nM peptide in each case). The cells were
then incubated at 37 ◦C in the dark for 4, 9 or 24 h. The media was then removed and
the cells washed once with HBSS to remove any phenol-red containing media. Cells were
subsequently fixed by incubating for 20 min at room temperature with 500 µL per well of
4% paraformaldehyde (diluted in HBSS).
Fixed cells were then washed twice in PBS followed by a 5-min incubation in 0.1 M
glycine (pH 7.4) at room temperature. They were then washed three times in PBS and their
nuclei stained with 4′,6-diamidino-2-phenylindole (DAPI 50 µg/mL in PBS) by incubation
for 1–2 min at room temperature. Another wash with PBS was then performed and
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the plastic chamber then detached from the glass slide. Any excess PBS was removed
and the slide mounted with Prolong Gold Antifade (Life Technologies). Once set, slides
were examined on a laser scanning (Nikon A1) confocal microscope equipped with FITC
(EX/EM 488/530 nM), Red (EX/EM 562/570 nM) and UV-Blue (EX/EM 405/480 nM)
filters. Pictures were then further analysed using Image J software.
2.6. Cytotoxicity Assay
The cytotoxic effect of increasing concentrations of Doxil®-p700-FITC compared with
Doxil-FITC and empty liposome-p700-FITC was evaluated using an MTS assay (CellTiter
96® AQueous, Promega, UK, Southampton). Cultured 4T1, H5V and HuDMEC cells at
around 80% confluence were trypsinised and then seeded at densities of 2 × 103 per well
containing 100 µL culture media in a 96-well plate and incubated at 37 ◦C overnight.
Cells were then treated with Doxil®-p700-FITC, Doxil-FITC, and empty liposome-
p700-FITC at 0, 2.5, 5, 10, 25, 50, and 100 µM doxorubicin concentration (or equivalent
liposome concentration for the empty liposomes) for 4 h at 37 ◦C, before being washed
three times with fresh media to remove any unbound drug. They were subsequently
incubated for a further 24 h in fresh media at 37 ◦C before an MTS assay was performed.
Each dose level was performed in triplicate and three independent repeat experiments
were completed.
Statistical analysis was performed using two-way ANOVA-multiple comparison test
and percentage cell viability curves were drawn using GraphPad Prism software v7.0.
2.7. Statistical Analysis
Experiments were performed in triplicate and data is presented as mean ± SEM
of three independent repeats (** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 indicates
significance, one or two-way ANOVA, multiple comparison test).
3. Results
3.1. Coupling Assessment
Flow cytometry confirmed the coupling of the azido-FITC peptides to either empty
DBCO-liposomes or DBCO-Doxil (Figure 1). As can be seen in panel (A) for azido-p700-
FITC and panel (B) for azido-FITC only, there was a pronounced shift in the green fluores-
cence associated with the liposomes before (blue peak) and after (green peak) coupling,
indicating efficient cross-linking of both azido-molecules to the liposomes. This result
was mirrored for coupling of azido-p700-FITC and azido-FITC only (panels (C) and (D)
respectively) to DBCO-Doxil. Although the background green fluorescence was slightly
higher for the Doxil than the empty liposomes prior to coupling (red peak), the shift
following coupling (green peak) was also more pronounced, again confirming efficient
coupling of both azido-FITC molecules to DBCO-Doxil. Panels (E) and (F) compare the red
fluorescence (associated with doxorubicin) of the final cross-linked products (blue peak,
empty liposomes and red peak, Doxil), which confirmed doxorubicin was still present in
the Doxil following coupling. Panels (E), for p700-FITC and (F), for FITC-only, compare
the red (doxorubicin) fluorescence of the empty liposomes (blue peaks) versus Doxil (red
peaks) following coupling, confirming the presence of doxorubicin in the coupled Doxil.
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Figure 1. Assessment of p700 coupling to PEGylated liposomes. Flow cytometric analysis of coupling
of: (A) empty DBCO-liposome to azido-p700-FITC; (B) empty DBCO-liposome to azido-FITC only;
(C) DBCO-Doxil to azido-p700-FITC; (D) DBCO-Doxil to azido-FITC only. Panels (A–D) show the
shift in green (FITC) fluorescence before (blue or red peaks) and after (green peaks) coupling. Panels
(E), for p700-FITC and (F), for FITC-only, compare the red (doxorubicin) fluorescence of the empty
liposomes (blue peaks) versus Doxil (red peaks) following coupling, confirming the presence of
doxorubicin in the coupled Doxil.
3.2. Binding Evaluation
Conjugates were then evaluated for binding to a panel of cell lines to determine
whether p700 enhances binding of Doxil to mouse and human breast tumour cell lines
(4T1 and MCF-7, respectively) or a mouse endothelial cell line (H5V) known to highly
express VEGFR2, relative to human primary microvascular endothelial cells (HuDMEC).
Doxil-FITC only was used as a negative control.
As shown in Figure 2A–C, 96–99% of the MCF-7, 4T1 and H5V cells treated with
Doxil-p700-FITC showed positive FITC staining, compared to 3% or less of those cells
treated with Doxil-FITC only. In contrast, only about 15% of HuDMEC showed positive
FITC staining with Doxil-p700-FITC (Figure 2D), with those treated with the Doxil-FITC
alone showing less than 2% positive FITC staining. This difference in staining between
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the cell lines and the primary microvascular endothelial cells was highly significant, as
illustrated in Figure 2E.
Figure 2. The effect of coupling p700 peptide on the binding of Doxil to cells. Bar charts showing
comparative flow cytometric data for the binding of Doxil-FITC or Doxil-p700-FITC to (A) MCF-7;
(B) 4T1; (C) H5V or (D) HuDMEC. (E) Relative binding of Doxil-p700-FITC to the above cell lines.
Percentages relate to numbers of cells with a fluorescence intensity above that of untreated cells. Data
are means ± SEM, n = 3 (**** p < 0.0001, * p < 0.01 indicates significance, one-way ANOVA, multiple
comparison test).
3.3. Cellular Uptake and Internalisation
The purpose of coupling p700 to Doxil was to specifically target the cytoxic drug
doxorubicin to tumour tissue. While flow cytometry confirmed that p700 greatly enhances
binding of Doxil to tumour cells and endothelial cells that show up-regulation of target
receptors (H5V), it is vital that the doxorubicin is then taken up by the cells in order to be
effective. Localisation of Doxil to the cell surface may be sufficient to enhance doxorubicin
uptake by the cells, however whether p700 would be internalised following binding and
thus potentially facilitate cellular entry of the doxorubicin, was unknown. To examine
cellular internalisation after binding, 4T1 cells were incubated with Doxil-FITC only or
Doxil-p700-FITC for 4, 9 and 24 h, after which cellular internalisation of both peptide (as
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determined by the FITC label) and doxorubicin (as determined by doxorubicin fluorescence)
were evaluated using confocal microscopy (Figure 3). In the absence of the p700 sequence,
no FITC fluorescence was seen to be associated with the cells (Figure 3A) although there
was some red fluorescence, presumably due to passive uptake of doxorubicin. In contrast,
in cells treated with Doxil-p700 (Figure 3B), there was very strong FITC fluorescence,
largely associated with what are probably endosomal granules in the cytoplasm, and this
co-localised with strong red fluorescence, presumed to be from the doxorubicin (observed
as a yellow colour in the merged images). Florescence was maximal at the 9-h time point,
becoming somewhat diminished at 24 h. The fact that the red fluorescence was due to
doxorubicin was confirmed by repeating the experiment with the empty liposomes coupled
to p700 (Figure 3C), where only green fluorescence was observed.
Figure 3. Uptake of Doxil, Doxil-p700 and empty liposome-p700 by the 4T1 cell line with time.
4T1 mouse breast cancer cells were treated with (A) Doxil-FITC; (B) Doxil-p700-FITC or (C) empty
liposome-p700 at 275 nM for 4, 9 and 24 h at 37 ◦C and then imaged by confocal microscopy. Red
staining is doxorubicin, green staining is FITC on the peptide conjugate and blue DAPI nuclear stain.
The experiment was then repeated for H5V, MCF-7 and HuDMEC (Figure 4), however
in this case only data for 9 h are shown as maximal fluorescence was seen at this time point.
Again, for H5V and MCF-7 (Figure 4A,B respectively), the p700 sequence greatly enhanced
uptake of FITC and doxorubicin, with no green and little red fluorescence observed in the
cells treated with Doxil-FITC only. However, for HuDMEC, no detectable green or red
fluorescence was observed with either Doxil-FITC or Doxil-p700-FITC, suggesting little
internalisation of the drug (Figure 4C).
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Figure 4. Uptake of Doxil and Doxil-p700 by H5V, MCF-7 and HuDMEC after 9 h. HV5 (A), MCF-
7 (B) or HuDMEC (C) were treated with Doxil-FITC or Doxil-p700-FITC, as indicated, at 275 nM for
9 h at 37 ◦C and then imaged by confocal microscopy. Red staining is doxorubicin, green staining is
FITC on the peptide conjugate and blue DAPI nuclear stain.
3.4. Cytotoxic Effect of Conjugates
Cytotoxicity of the conjugates towards MCF-7, 4T1, H5V and HuDMEC was deter-
mined 24 h after a 4-h exposure to varying concentrations of Doxil-p700-FITC or Doxil-FITC.
Empty liposome-p700-FITC was used as a control to confirm any cytotoxicity seen was due
to the doxorubicin content of the Doxil and not the liposome or p700 peptide. As shown
in Figure 5, 4T1, MCF-7 and H5V cells treated with the highest dose of Doxil-p700-FITC
all showed a significant increase in cell death, relative to both empty p700-liposomes and
Doxil-FITC only. While the HuDMECs also showed a significant increase in cell death with
Doxil-p700, relative to the empty p700-liposomes, this was not significantly greater than
that seen with Doxil-FITC only.
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Figure 5. Effect of increasing concentrations of empty liposome—p700 FITC, Doxil-FITC and Doxil-p700-FITC on cell
viability. 4T1 (A), MCF-7 (B), H5V (C) or HuDMEC (D) were treated for 4 h with the stated dose of each agent, as indicated
in the key, washed and then incubated for a further 24 h in complete growth medium before performing an MTS cell
viability assay. Data are means ± SEM, n = 3 (** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 indicates significance, two-way
ANOVA, multiple comparison test).
4. Discussion
The data reported herein confirm that p700 retains its ability to target tumours and
tumour vasculature via tyrosine kinase receptors when covalently cross-linked to PEGy-
lated liposomes and that this clearly enhances uptake of Doxil into these cells. However
enhanced internalisation does not necessarily equate to enhanced cytotoxicity if the dox-
orubicin is retained in endosomes and cannot reach the nucleus. After internalisation of
liposomal drugs, the liposome is usually metabolised in the endolysosomal pathway where
the liposome is degraded by the acidic medium of the lysosome [30]. The reduction in
Doxil-p700-FITC concentration in the cytoplasm after 9 h could be because of degradation
of the peptide and the liposome. However, the fact that there was a clear enhancement of
cytotoxicity of Doxil-p700 over Doxil only, for all the cancer cell lines at 100 µM, indicates
that at least some of the doxorubicin is then released to the nucleus. Although it is clearly
difficult to compare treatment of cells in vitro in a static culture with the in vivo situation,
the maximum recommended clinical dose for Doxil is 50 mg/m2 [31], which would be in
the order of 30 µM blood concentration of doxorubicin. As the p700-Doxil is expected to be
highly concentrated within the tumour microenvironment, it does not seem unreasonable
to expect a concentration of 100 µM to be achievable in this millieu.
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Binding of Doxil-p700-FITC was clearly evident by the much higher percentage of
FITC positive population in the second quadrant of, respectively, MCF-7 96.4%, 4T1 99.7%,
and H5V 99.0% compared to primary HuDMEC, which showed only 15% positive cells
for binding. This may be an indication of the highly expressed receptors on cancer cells
that can bind p700, those which are less expressed in normal cells such as the case with
HuDMEC.
Binding and uptake of Doxil-p700 by the human MCF-7 breast tumour cells was
somewhat less than for the mouse 4T1 breast tumour cells and this may explain the reduced
killing of MCF-7 relative to 4T1 tumours. However, MCF-7 is also known to be resistant to
doxorubicin with specific point mutations shown to confer this cell line with resistance to
anthracyclines [32]. Indeed, this is probably reflected in Figure 5, in which MCF-7 is the
only cell line where Doxil alone is not cytotoxic, relative to the empty liposomes. The fact
that Doxil-p700 does still show some killing of this cell line demonstrates the benefit of
targeted delivery over conventional methods.
Perhaps surprisingly, uptake of Doxil-p700 by tumour cells was much greater than for
primary human microvascular endothelial cells (HuDMEC), despite the fact that these cells
do bear VEGFR2. In contrast uptake by the H5V mouse endothelial cell line was much
higher. This may, in part, be due to the differential expression of VEGFR2 by these cells and
could be said to mimic the fact that VEGFR2 is upregulated in tumour microvasculature
compared to normal tissue. It is also possible that, as a retrovirally transformed cell line [33],
H5V also bears FGF and/or PDGF receptors, which are not expressed significantly by
HuDMEC. Despite this, Doxil-p700 did show significant killing of HuDMECs, relative
to the empty liposomes. However, this probably reflects the fact that primary cells lack
some of the drug resistance mechanisms of tumour cells and in fact the level of killing seen
with Doxil-p700 was no greater than for Doxil alone, suggesting that the doxorubicin was
largely internalised passively into these cells. Moreover, normal vasculature is unlikely to
be exposed to such high concentrations of Doxil-p700 as the tumour tissue where it should
be concentrated. Binding of the p700-Doxil conjugates to the cell surface was supposed
to facilitate internalisation by the cells. It might be noticeable that the uptake result in
the confocal image does not reflect the binding of the conjugate to cell surface in the flow
cytometry. This is because only 15% of the cells showed binding to cell surface which
would translate to reduced probability of internalisation or uptake of the conjugate in
HuDMEC as seen by nearly no florescence. However, over 90% binding in the cancer cells
resulted in significantly higher uptake of the conjugate.
In this study, we sought to exploit the multi-receptor binding profile of p700 [16]
to target PEGylated doxorubicin (Doxil) to tumour cells. Although this is not a novel
concept, p700 may offer several advantages over conventional peptides or antibodies.
As far as we are aware, p700 is unique in being able to target multiple pro-angiogenic
growth factor receptors known to be upregulated in tumours or tumour vasculature, giving
it the potential to target a wide range of tumours with high avidity due to multivalent
binding. Targeting multiple receptors also greatly decreases the likelihood of tumour cells
developing resistance due to downregulation or mutation of any one receptor type. An
alternative approach, previously used, has been to exploit cell-penetrating peptides such
as those derived from TAT [15], although such peptides are not tumour specific and so risk
increased off-target effects.
Usually, ligands targeting multiple receptors are often characterised with varying
specificity for their targets [34], which is a likely problem for p700. However, the receptors
inhibited by p700 are a small, closely related group of proangiogenic tyrosine kinase
receptors that are not highly expressed by normal cells. Thus, p700 is expected to be highly
specific to tumours. There are plenty of mono-specific molecules available but these are
highly vulnerable to tumour drug resistance due to mutation. Likewise, there are much
broader small molecule inhibitors that target several tyrosine kinases such as Sorafenib
and Sunitinib, which have been approved for cancer treatment [35]. These molecules also
inhibit some intracellular tyrosine kinases, potentially increasing off-target effects. The
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potential advantage of p700 is its specificity for a narrow range of extracellular tyrosine
kinase receptors and this can be employed to deliver any payload that can be encapsulated
in liposomes.
In addition to binding multiple targets, p700 also has several advantages over using
monoclonal antibodies to target liposomes. The latter are expensive to develop and pro-
duce, require humanization to prevent an immune response and show decreased tissue
penetration due to their large size. In contrast, p700 is only 16 amino acids long and is
derived from a highly conserved secreted human protein, so that immunogenicity is much
less likely to be an issue.
While there are several small molecule drugs that also target a wider family of tyrosine
kinase receptors, such as sorafenib and sunitinib, these all target the intracellular kinase
domain and can also target other intracellular kinases with the potential for off-target
effects [36]. Using extracellular, competitive inhibitors of these receptors to target liposomes
should decrease the likelihood of side-effects and enable the deliver any drug that can be
encapsulated in this way.
5. Conclusions
The data presented here demonstrate that Doxil-p700 has significant potential as a
cancer therapeutic with the ability to actively target doxorubicin to tumour tissue. En-
hanced localisation to the tumour may decrease circulation time throughout the body,
relative to unmodified Doxil, potentially reducing off target effects such as palmar planter
erythrodysesthesia. Additionally, p700 enabled active internalisation of the conjugate,
potentially enhancing drug delivery into the tumour cells. While some cells, such as MCF-7,
show resistance to doxorubicin, the other advantage of this technique is that it can be used
to target any drug that can be encapsulated in this way.
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